These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33324410)

  • 1. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
    Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
    Front Immunol; 2020; 11():593863. PubMed ID: 33324410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
    Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
    Front Immunol; 2020; 11():558143. PubMed ID: 33178187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.
    Mammadli M; Huang W; Harris R; Xiong H; Weeks S; May A; Gentile T; Henty-Ridilla J; Waickman AT; August A; Bah A; Karimi M
    iScience; 2021 Apr; 24(4):102286. PubMed ID: 33851101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
    Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
    Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
    Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
    Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.
    Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK
    Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.
    Hanash AM; Kappel LW; Yim NL; Nejat RA; Goldberg GL; Smith OM; Rao UK; Dykstra L; Na IK; Holland AM; Dudakov JA; Liu C; Murphy GF; Leonard WJ; Heller G; van den Brink MR
    Blood; 2011 Jul; 118(2):446-55. PubMed ID: 21596854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
    Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
    Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects.
    Liang Y; Liu C; Djeu JY; Zhong B; Peters T; Scharffetter-Kochanek K; Anasetti C; Yu XZ
    Blood; 2008 Jan; 111(2):954-62. PubMed ID: 17928532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice.
    Kim S; Lim S; Kim B; Ritchey J; Vij K; Prior J; Marsala L; Stoner A; Gao F; Achilefu S; Cooper ML; DiPersio JF; Choi J
    Blood; 2023 Feb; 141(8):945-950. PubMed ID: 36477272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.